Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jan 31;105(2):249-251.
doi: 10.3324/haematol.2019.238857. Print 2020.

Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people

Gunnar Juliusson  1 , Martin Höglund  2 , Sören Lehmann  2   3
Affiliations
Editorial

Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people

Gunnar Juliusson et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mechanisms of action of hypomethylating agents, and overall survival of Swedish patients 70 years and older by treatment. (A) Mechanism of action for treatment with hypomethylating agents (HMA). DNA methyl transferases (DNMT). (B) Overall survival (OS) according to therapy. Acute promyelocytic leukemia is excluded (non-APL). All patients 70 years and older. HMA versus intensive treatment; P=0.056. (C) de novo acute myeloid leukemia (AML). HMA versus intensive treatment; P=0.028. (D) AML secondary to previous myelodysplastic syndromes (MDS), myeloproliferative neoplasia (MPN) or chemo-radiotherapy (secAML). HMA versus intensive treatment; P=0.33.
See this image and copyright information in PMC

Comment on

References

    1. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. - PMC - PubMed
    1. Yates JW, Wallace HJ, Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (nsc-83142) therapy in nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488. - PubMed
    1. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590. - PubMed
    1. Juliusson G, Hagberg O, Lazarevic VL, et al. Improved survival of men 50-75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134(18):1558–1561. - PMC - PubMed
    1. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187. - PubMed